Showing results (61-70 of 77) with videos related to
Sort By:
Pageof 8
Histopathology|May 13, 2010
High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtypeSarah J Zardawi, Ibrahim Zardawi, Catriona M McNeil, et al.International Journal of Cancer|August 14, 2009
Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative statusNiamh C Murphy, Andrew V Biankin, Ewan K A Millar, et al.The FEBS Journal|July 24, 2013
Global characterization of signalling networks associated with tamoxifen resistance in breast cancerBrigid C Browne, Falko Hochgräfe, Jianmin Wu, et al.Cancer Research|June 3, 2011
Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancerSandra A O'Toole, Dorothy A Machalek, Robert F Shearer, et al.Cancer|October 15, 2014
Clinical and pathologic features of familial pancreatic cancerJeremy L Humphris, Amber L Johns, Skye H Simpson, et al.Gastroenterology|April 21, 2009
Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancerAndrew V Biankin, James G Kench, Emily K Colvin, et al.Genome Medicine|September 6, 2013
Clinical and molecular characterization of HER2 amplified-pancreatic cancerAngela Chou, Nicola Waddell, Mark J Cowley, et al.Annals of Surgery|July 18, 2020
Precision Oncology in Surgery: Patient Selection for Operable Pancreatic CancerStephan B Dreyer, Mark Pinese, Nigel B Jamieson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2013
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vaterDavid K Chang, Nigel B Jamieson, Amber L Johns, et al.Cell Reports|May 14, 2020
HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic CancerHolly Brunton, Giuseppina Caligiuri, Richard Cunningham, et al.Pageof 8